These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6693797)

  • 1. Changes in the pharmacology of warfarin during long-term administration in dogs.
    Covell DG; Abbrecht PH; Powers WF
    J Lab Clin Med; 1984 Feb; 103(2):272-83. PubMed ID: 6693797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence, magnitude, and time course of the amiodarone-warfarin interaction.
    Kerin NZ; Blevins RD; Goldman L; Faitel K; Rubenfire M
    Arch Intern Med; 1988 Aug; 148(8):1779-81. PubMed ID: 3401099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirements.
    Weiss P; Halkin H; Almog S
    Thromb Haemost; 1986 Dec; 56(3):371-5. PubMed ID: 3563968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting warfarin maintenance dosage based on initial response.
    Miller DR; Brown MA
    Am J Hosp Pharm; 1979 Oct; 36(10):1351-5. PubMed ID: 507078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response.
    Lee C; Coleman RW; Mungall DR
    Clin Pharm; 1987 May; 6(5):406-12. PubMed ID: 3665392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response.
    Sawyer WT; Poe TE; Canaday BR; Weiner JS; Williams DM; Webb CE; Ellison MJ
    Clin Pharm; 1985; 4(4):440-6. PubMed ID: 3899472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma warfarin levels and variations in steady-state prothrombin times.
    White RH; Zhou H; Romano P; Mungall D
    Clin Pharmacol Ther; 1995 Nov; 58(5):588-93. PubMed ID: 7586953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a potential tigecycline-warfarin drug interaction.
    Zimmerman JJ; Raible DG; Harper DM; Matschke K; Speth JL
    Pharmacotherapy; 2008 Jul; 28(7):895-905. PubMed ID: 18576904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy.
    Carter BL; Taylor JW; Becker A
    Clin Pharm; 1987 Jan; 6(1):37-45. PubMed ID: 3816105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidotal effect of vitamin K1 against warfarin-induced anticoagulation in horses.
    Byars TD; Greene CE; Kemp DT
    Am J Vet Res; 1986 Oct; 47(10):2309-12. PubMed ID: 3777660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
    Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
    Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
    Neal JM; Kunze KL; Levy RH; O'Reilly RA; Trager WF
    Drug Metab Dispos; 2003 Aug; 31(8):1043-8. PubMed ID: 12867493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy.
    Raj G; Kumar R; McKinney WP
    Arch Intern Med; 1995 Jul; 155(14):1529-31. PubMed ID: 7605155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium.
    Crussell-Porter LL; Rindone JP; Ford MA; Jaskar DW
    Arch Intern Med; 1993 Jan; 153(1):102-4. PubMed ID: 8422191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A; Depré M; Verbesselt R; Wynants K; De Lepeleire I; Arnout J; Wong PH; Freeman A; Holland S; Gertz B; De Schepper PJ
    J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.